These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8291918)

  • 1. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
    Ohno R; Yoshida Y; Oguro M; Ogawa M; Sakai Y; Furue H; Ariyoshi Y; Saito H; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):75-82. PubMed ID: 8291918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
    Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
    Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
    Ohno R; Okada K; Masaoka T; Kuramoto A; Arima T; Yoshida Y; Ariyoshi H; Ichimaru M; Sakai Y; Oguro M
    J Clin Oncol; 1990 Nov; 8(11):1907-12. PubMed ID: 2230878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
    Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
    Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
    Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
    Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
    Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
    Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
    Saotome T; Takagi T; Sakai C; Kumagai K; Tamaru J
    Ann Oncol; 2000 Jan; 11(1):115-6. PubMed ID: 10690400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
    Takagi T; Saotome T
    Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
    Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
    Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Takamizawa H; Takeda Y; Ohkawa T; Tamaya T; Noda K; Sugawa T; Sekiba K; Yakushiji M; Taguchi T
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):579-84. PubMed ID: 2012400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
    Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
    Negoro S; Fukuoka M; Niitani H; Suzuki A; Nakabayashi T; Kimura M; Motomiya M; Kurita Y; Hasegawa K; Kuriyama T
    Gan To Kagaku Ryoho; 1991 May; 18(6):1013-9. PubMed ID: 1851408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPT-11: clinical experience in phase I studies.
    Armand JP
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):27-33. PubMed ID: 8633250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.